Labetalol

Major

Labetalol Albuterol Oral Inhalation Accuneb® Explained Reduced efficacy of albuterol Details Labetalol Azathioprine Azasan An increased risk of hepatotoxicity Details Labetalol Clonidine Transdermal Patch Catapres An increased risk of worsen sinus node dysfunction and atrioventricular node conduction, an increased risk of bradycardia and AV b... Details Labetalol Indacaterol Oral Inhalation Arcapta® Decreased efficacy of indacaterol Details Labetalol Albuterol ProAir Reduced efficacy of albuterol Details Labetalol Apalutamide Erleada Reduced CYP2C19 substrate exposure Details Labetalol Cannabidiol Epidiolex Increased CYP2C19 substrate exposure and an increased risk of CYP2C19 substrate-related adverse reactions Details Labetalol Carbamazepine Carbatrol Reduced CYP2C19 substrate exposure and reduced efficacy of CYP2C19 substrate Details Labetalol Ceritinib Zykadia Increased risk of bradycardia Details Labetalol Clomipramine Anafranil Increased clomiPRAMINE exposure Details Labetalol Clonidine Duraclon An increased risk of worsen sinus node dysfunction and atrioventricular node conduction, an increased risk of bradycardia and AV b... Details Labetalol Crizotinib Xalkori An increased risk of bradycardia Details Labetalol Darunavir Increased beta blocker exposure and an increased risk of beta blocker-related adverse effects Details Labetalol Dextroamphetamine Dexedrine Increased dextroamphetamine or lisdexamfetamine (prodrug of dextroamphetamine) exposure and an increased risk of serotonin syndrom... Details Labetalol Diltiazem Cardizem An increased risk of hypotension, bradycardia and slow AV conduction Details Labetalol Dronedarone Multaq Increased exposure to some beta blockers and increased incidence of bradycardia Details Labetalol Epinephrine Antagonized cardio stimulating and bronchodilation effects of EPINEPHrine, an increased risk of severe hypertension and an increas... Details Labetalol Fenoldopam Exaggeration of hypotensive response Details Labetalol Fexinidazole Increased risk of bradycardia Details Labetalol Fingolimod Gilenya Slowing of the heart rate or atrioventricular conduction, which may result in severe bradycardia or heart block Details Labetalol Formoterol Perforomist Reduced efficacy of formoterol or reduced efficacy of beta-adrenergic blocker Details Labetalol Haloperidol Increased haloperidol exposure and an increased risk of haloperidol-related adverse events, including QTc interval prolongation Details Labetalol Halothane Hypotension or decreased cardiac output Details Labetalol Indacaterol Decreased efficacy of indacaterol Details Labetalol Insulin Afrezza Increased or reduced blood glucose lowering effect of insulin and reduced symptoms of hypoglycemia Details Labetalol Insulin Icodec-Abae Awiqli An increased risk of hypoglycemia, which may sometimes be followed by hyperglycemia and an increased risk of blunted recognition o... Details Labetalol Iobenguane I 123 Potential for false negative imaging results Details Labetalol Iobenguane I 131 Azedra Inaccurate dosimetry calculations or reduced efficacy Details Labetalol Iohexol Lower threshold for contrast reactions, increased risk of more severe contrast reaction, reduced efficacy when treating hypersensi... Details Labetalol Lacosamide Motpoly An increased risk of AV block, bradycardia, and ventricular tachyarrhythmia Details Labetalol Landiolol An increased risk of myocardial contractility depression and increase the risk of bradycardia or heart block Details Labetalol Levalbuterol Xopenex Reduced efficacy of levalbuterol Details Labetalol Levoketoconazole Recorlev Increased risk of serious hepatotoxicity and drug-induced liver injury Details Labetalol Lisdexamfetamine Arynta Increased dextroamphetamine or lisdexamfetamine (prodrug of dextroamphetamine) exposure and an increased risk of serotonin syndrom... Details Labetalol Lonafarnib Zokinvy Increased CYP2C19 substrate exposure and an increased risk of CYP2C19 substrate-related adverse effects Details Labetalol Melatonin An increased risk of suppression of endogenous melatonin levels Details Labetalol Mercaptopurine Purinethol® An increased risk of hepatotoxicity Details Labetalol Methotrexate Jylamvo Increased methotrexate exposure, an increased risk of methotrexate-related severe adverse reactions, reduced active metabolite for... Details Labetalol Methylergonovine Methergine An increased risk of enhanced vasoconstrictive Details Labetalol Olodaterol Striverdi Reduced olodaterol exposure and reduced beta-adrenergic blockers exposure Details